临床试验中基于自然杀伤T细胞的免疫疗法。 - Suppr

NKT-cell-based immunotherapies in clinical trials.

作者信息

Exley Mark A, Nakayama Toshinori

出版信息

Clin Immunol. 2011 Aug;140(2):117-8. doi: 10.1016/j.clim.2011.04.015. Epub 2011 Apr 28.

DOI:10.1016/j.clim.2011.04.015

PMID:21592864

Abstract

摘要

相似文献

NKT-cell-based immunotherapies in clinical trials.

Clin Immunol. 2011 Aug;140(2):117-8. doi: 10.1016/j.clim.2011.04.015. Epub 2011 Apr 28.

Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.

Clin Immunol. 2011 Aug;140(2):119-29. doi: 10.1016/j.clim.2010.10.005. Epub 2010 Nov 20.

Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.

J Vis Exp. 2007(10):635. doi: 10.3791/635. Epub 2007 Dec 31.

Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.

Tissue Antigens. 2009 Jun;73(6):535-45. doi: 10.1111/j.1399-0039.2009.01256.x. Epub 2009 Apr 8.

[Recognition of CD1d/glycolipid antigen complex by NKT cells and mechanisms in immune regulation].

Tanpakushitsu Kakusan Koso. 2008 Sep;53(12 Suppl):1584-9.

Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy.

Proc Jpn Acad Ser B Phys Biol Sci. 2015;91(7):292-304. doi: 10.2183/pjab.91.292.

Immune evasion of the CD1d/NKT cell axis.

Curr Opin Immunol. 2018 Jun;52:87-92. doi: 10.1016/j.coi.2018.04.021. Epub 2018 May 4.

IFN-γ production downstream of NKT cell activation in mice infected with influenza virus enhances the cytolytic activities of both NK cells and viral antigen-specific CD8+ T cells.

Virology. 2010 Nov 25;407(2):325-32. doi: 10.1016/j.virol.2010.08.030. Epub 2010 Sep 19.

Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.

J Immunol. 2009 Jun 15;182(12):7644-54. doi: 10.4049/jimmunol.0900134.

Antigen recognition by CD1d-restricted NKT T cell receptors.

Semin Immunol. 2010 Apr;22(2):61-7. doi: 10.1016/j.smim.2009.10.004. Epub 2009 Nov 28.

引用本文的文献

A Humanized Mouse Model Coupled with Computational Analysis Identifies Potent Glycolipid Agonist of Invariant NKT Cells.

ACS Chem Biol. 2024 Apr 19;19(4):926-937. doi: 10.1021/acschembio.3c00736. Epub 2024 Mar 13.

A humanized mouse model for evaluation of invariant Natural Killer T cell responses.

Front Immunol. 2022 Oct 3;13:1011209. doi: 10.3389/fimmu.2022.1011209. eCollection 2022.

Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.

Cancer Res. 2021 Apr 1;81(7):1788-1801. doi: 10.1158/0008-5472.CAN-20-2219. Epub 2021 Jan 22.

Mouse CD8NKT-like cells exert dual cytotoxicity against mouse tumor cells and myeloid-derived suppressor cells.

Cancer Immunol Immunother. 2019 Aug;68(8):1303-1315. doi: 10.1007/s00262-019-02363-3. Epub 2019 Jul 5.

α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials.

Front Immunol. 2019 Jun 6;10:1126. doi: 10.3389/fimmu.2019.01126. eCollection 2019.

Photoactivable Glycolipid Antigens Generate Stable Conjugates with CD1d for Invariant Natural Killer T Cell Activation.

Bioconjug Chem. 2018 Sep 19;29(9):3161-3173. doi: 10.1021/acs.bioconjchem.8b00484. Epub 2018 Aug 23.

Program Cell Death Receptor-1-Mediated Invariant Natural Killer T-Cell Control of Peritoneal Macrophage Modulates Survival in Neonatal Sepsis.

Front Immunol. 2017 Nov 20;8:1469. doi: 10.3389/fimmu.2017.01469. eCollection 2017.

Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.

Oncoimmunology. 2017 Aug 18;6(9):e1339855. doi: 10.1080/2162402X.2017.1339855. eCollection 2017.

Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.

Front Immunol. 2017 Jul 27;8:879. doi: 10.3389/fimmu.2017.00879. eCollection 2017.

CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.

J Clin Invest. 2016 Jun 1;126(6):2341-55. doi: 10.1172/JCI83476. Epub 2016 May 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

NKT-cell-based immunotherapies in clinical trials.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献